We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Adaptive Biotechnologies (ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adaptive Biotechnologies is one of 1011 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 2.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ADPT has returned about 30.1% since the start of the calendar year. At the same time, Medical stocks have gained an average of 5%. As we can see, Adaptive Biotechnologies is performing better than its sector in the calendar year.
Another stock in the Medical sector, Castle Biosciences, Inc. (CSTL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 5.5%.
In Castle Biosciences, Inc.'s case, the consensus EPS estimate for the current year increased 19.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry, a group that includes 510 individual companies and currently sits at #72 in the Zacks Industry Rank. Stocks in this group have gained about 11% so far this year, so ADPT is performing better this group in terms of year-to-date returns. Castle Biosciences, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Adaptive Biotechnologies and Castle Biosciences, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Adaptive Biotechnologies (ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adaptive Biotechnologies is one of 1011 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 2.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ADPT has returned about 30.1% since the start of the calendar year. At the same time, Medical stocks have gained an average of 5%. As we can see, Adaptive Biotechnologies is performing better than its sector in the calendar year.
Another stock in the Medical sector, Castle Biosciences, Inc. (CSTL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 5.5%.
In Castle Biosciences, Inc.'s case, the consensus EPS estimate for the current year increased 19.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry, a group that includes 510 individual companies and currently sits at #72 in the Zacks Industry Rank. Stocks in this group have gained about 11% so far this year, so ADPT is performing better this group in terms of year-to-date returns. Castle Biosciences, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Adaptive Biotechnologies and Castle Biosciences, Inc. as they attempt to continue their solid performance.